NCT02506023View on ClinicalTrials.gov

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 15, 2018

Study Completion Date

June 15, 2018

Conditions
Hemophilia A
Interventions
DRUG

Desmopressin

Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.

Trial Locations (2)

30322

Children's Hospital of Atlanta Egleston, Atlanta

Emory University, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT02506023 - Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers | Biotech Hunter | Biotech Hunter